Expected deaths in etanercept trials for rheumatic conditions
| Age <65 years | Age ⩾65 years | |||||
|---|---|---|---|---|---|---|
| Expected* | Observed | SIR† (95% CI) | Expected* | Observed | SIR† (95% CI) | |
| SIR, standardised incidence ratio; CI, confidence interval; RA, rheumatoid arthritis; PsA, psoriatic arthritis; AS, ankylosing spondylitis; N/A, not applicable | ||||||
| *Expected number of deaths per National Vital Statistics Report for 199951; †standardised incidence ratio for observed deaths/expected deaths. | ||||||
| RA | 28.9 | 20 | 0.69 (0.42 to 1.07) | 29.0 | 20 | 0.69 (0.42 to 1.07) |
| PsA | 1.1 | 1 | 0.91 (0.02 to 5.07) | 0.4 | 0 | 0.00 (0.00 to 9.22) |
| AS | 0.2 | 0 | 0.00 (0.00 to 18.44) | 0.0 | 0 | N/A |